title: CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.
abstract: This retrospective study was designed to investigate the correlation between a novel immunosubtyping method for hepatocellular carcinoma (HCC) and biological behavior of tumor cells. A series of 346 patients, who received hepatectomy at two surgical centers from January 2007 to October 2010, were enrolled in this study. The expressions of cytokeratin 19 (CK19), glypican 3 (GPC3), and CD34 were detected by immunohistochemical staining. The clinical stage was assessed using the sixth edition tumor-node-metastasis (TNM) system (UICC/AJCC, 2010).Vascular invasion comprised both microscopic and macroscopic invasion. The tumor size, lymph node involvement, and metastasis were determined by pathological as well as imaging studies. Recurrence was defined as the appearance of new lesions with radiological features typical of HCC, seen by at least two imaging methods. Survival curves for the patients were plotted using the Kaplan-Meier method, and differences between the curves were assessed using the log-rank test. Significant differences in morphology, histological grading, and TNM staging were observed between groups. Based on the immunohistochemical staining, the enrolled cases were divided into CK19+/GPC3+, CK19-/GPC3+ and CK19-/GPC3- three subtypes. CK19+/GPC3+ HCC has the highest risk of multifocality, microvascular invasion, regional lymph node involvement, and distant metastasis, followed by CK19-/GPC3+ HCC, then CK19-/GPC3-HCC. CK19+/GPC3+ HCC has the shortest recurrence time compared to other immunophenotype HCCs. CK19 and GPC3 expression profiling is an independent prognostic indicator in patients with HCC, and a larger sample size is needed to further investigate the effect of this immunosubtyping model in stratifying the outcome of HCC patients.
authors.affiliation: Clinical-Pathology Center, Beijing You-An Hospital, Capital Medical University, Beijing, 100069, China.
authors.forename: Jiliang
authors.initials: J
authors.lastname: Feng
authors.affiliation: Surgical Center, Beijing You-An Hospital, Capital Medical University, Beijing, 100069, China.
authors.forename: Ruidong
authors.initials: R
authors.lastname: Zhu
authors.affiliation: Department of Respiratory Diseases, Peking University Third Hospital, Beijing, 100191, China.
authors.forename: Chun
authors.initials: C
authors.lastname: Chang
authors.affiliation: Clinical-Pathology Center, Beijing You-An Hospital, Capital Medical University, Beijing, 100069, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Yu
authors.affiliation: Clinical-Pathology Center, Beijing You-An Hospital, Capital Medical University, Beijing, 100069, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Cao
authors.affiliation: Clinical-Pathology Center, Beijing You-An Hospital, Capital Medical University, Beijing, 100069, China.
authors.forename: Guohua
authors.initials: G
authors.lastname: Zhu
authors.affiliation: Department of Radiology, Beijing You-An Hospital, Capital Medical University, Beijing, 100069, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Chen
authors.affiliation: The 304th Hospital of PLA, Beijing, 100048, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Xia
authors.affiliation: Department of Pathology, Beijing You-An Hospital, Capital Medical University, Beijing, 100069, China.
authors.forename: Fudong
authors.initials: F
authors.lastname: Lv
authors.affiliation: Department of Pathology, Beijing You-An Hospital, Capital Medical University, Beijing, 100069, China.
authors.forename: Shijie
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Department of Pathology, Beijing You-An Hospital, Capital Medical University, Beijing, 100069, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Sun
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000556:secondary / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D020869:Gene Expression Profiling; D053673:Glypicans / Q000032:analysis* / Q000096:biosynthesis / Q000235:genetics; D006498:Hepatectomy; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D053539:Keratin-19 / Q000032:analysis* / Q000096:biosynthesis / Q000235:genetics; D008113:Liver Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000032:analysis* / Q000096:biosynthesis / Q000235:genetics; D009367:Neoplasm Staging; D010641:Phenotype; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018401:Sample Size; D016037:Single-Blind Method
chemical_list: C105937:GPC3 protein, human; D053673:Glypicans; D053539:Keratin-19; D009363:Neoplasm Proteins